88,527 Shares in Progyny, Inc. (NASDAQ:PGNY) Bought by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 88,527 shares of the company's stock, valued at approximately $1,484,000. GSA Capital Partners LLP owned approximately 0.10% of Progyny as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PGNY. Quarry LP increased its holdings in Progyny by 1,900.0% during the 2nd quarter. Quarry LP now owns 880 shares of the company's stock valued at $25,000 after acquiring an additional 836 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Progyny during the 2nd quarter valued at about $44,000. Mendota Financial Group LLC purchased a new position in Progyny during the 3rd quarter valued at about $56,000. Cambridge Trust Co. purchased a new position in Progyny during the 1st quarter valued at about $95,000. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Progyny during the 2nd quarter worth about $97,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PGNY shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of Progyny in a research note on Tuesday, October 1st. Jefferies Financial Group decreased their price target on shares of Progyny from $31.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, September 19th. BTIG Research cut shares of Progyny from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 7th. Canaccord Genuity Group decreased their price target on shares of Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research note on Wednesday. Finally, Canaccord Genuity Group cut shares of Progyny from a "buy" rating to a "hold" rating and decreased their price target for the stock from $37.00 to $24.00 in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Progyny currently has an average rating of "Hold" and a consensus price target of $25.42.

Progyny Price Performance

NASDAQ PGNY traded up $0.25 during mid-day trading on Thursday, hitting $14.15. The company's stock had a trading volume of 753,996 shares, compared to its average volume of 1,387,047. Progyny, Inc. has a 52-week low of $13.77 and a 52-week high of $42.08. The stock's fifty day simple moving average is $17.69 and its two-hundred day simple moving average is $23.56. The firm has a market capitalization of $1.28 billion, a P/E ratio of 23.97, a price-to-earnings-growth ratio of 1.62 and a beta of 1.44.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The firm had revenue of $286.63 million for the quarter, compared to analysts' expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 10.87%. The company's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.16 EPS. On average, equities analysts forecast that Progyny, Inc. will post 0.64 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.